AML Flashcards

1
Q

What syndrome is associated with JMML? What is the typical mutation associated with that syndrome?

A

Noonan syndrome, PTPN11

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Updated JMML criteria

A

LEVEL 1 (all 4 required):

  • Splenomegaly,
  • Monocytosis >1*10¨9 in PB
  • Less than 20% blasts in BM,
  • BCR-ABL (-)ve

LEVEL 2 (1 required):

  • Somatic mutation of n-ras, k-ras, PTPN11
  • NF1
  • Germline mutation of CBL

LEVEL 3 (2 required if no level 2 criteria)

  • Increase in myeloid precursors
  • Elevated Hgb F
  • Hyperphosphorylation of STAT5
  • Hypersensitivity to GM-CSF
  • Monosomy 7, or other clonal abnormalities
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Transient abnormal myelopoiesis:

  • Incidence in patient with Down syndrome?
  • % of patients with TAM who will develop AMKL
A

10%

20-30%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cytogenetics associated with transient abnormal myelopoiesis;
Cytogenetics associated with transformation into AMKL

A

GATA1

+trisomy 8 , TP53

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Natural history of transient myeloproliferative disorder associated with Down syndrome

A

Spontaneous regression in majority of cases within 3 months; minority of patients can develop life-threatening conditions
(hyperviscosity, hydrops fetalis, cardiac failure, massive organomegaly with respiratory compromise, severe hepatic dysfunction, etc.)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Common cytogenetic abnormality in non-DS related AMKL

A

T(1;22)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Genes associated with familial MDS/AML syndrome (3)

A

CEPBA: mostly AML, very penetrant
GATA2: involved in blood, vascular and lymphatic development; not full penetrant, associated as well with mono-MAC syndrome
RUNX1: also associated with thrombocytopenia and platelet dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the recommended follow up after TAM?

A
  • Clinical assessment, CBC/diff q1 month until 3 m.o. or normalization of counts
    After normalization of blood counts
  • Clinical assessment, CBC/diff, blood smear q3 months until 4 y.o.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the molecular signature of APML?

A

PML-RARa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What symptoms are seen in differentiation syndrome?

A

Fever
Respiratory distress, hypoxia, pulm infiltrates
Pleural or pericardial effusion, peripheral edema, weight gain, congestive heart failure, hypotension
Erythematous rash
Acute kidney injury

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the management of differentiation syndrome?

A
  • Dexamethasone to be started promptly
  • Hold offending agents (ATRA, arsenic)
  • Supportive care, including hydration and furosemide if needed
How well did you know this?
1
Not at all
2
3
4
5
Perfectly